Pisitkun T, Jacob V, Schleicher SM, Chou C-L, Yu M-J, Knepper MA. Akt and ERK1/2 pathways are components of the vasopressin signaling network in rat native IMCD. Am J Physiol Renal Physiol 295: F1030 -F1043, 2008. First published July 30, 2008 doi:10.1152/ajprenal.90339.2008.-Vasopressin regulates water excretion through effects on the renal collecting duct. Vasopressin signaling in the inner medullary collecting duct (IMCD) is mediated by V2 receptor occupation coupled to the generation of cyclic AMP. Here, we employ a "systems" approach to analysis of vasopressin signaling. The objective is to investigate roles of activation of the Akt and ERK1/2 MAP kinase pathways, as well as Ca 2ϩ mobilization, in IMCD cells isolated from rat kidney. The V2 receptor-selective vasopressin analog dDAVP increased the state of Akt activation (increased phosphorylation at T308 and S473) and decreased the state of ERK1/2 activation (decreased phosphorylation at T202 and Y204). Akt activation was blocked by an inhibitor of PI3K, LY294002. In microdissected IMCD segments, nonperiodic spike-like increases in intracellular Ca 2ϩ (FLUO-4) were accelerated by vasopressin. Chelation of Ca 2ϩ or calmodulin inhibition markedly decreased Akt phosphorylation. Decreased ERK1/2 phosphorylation was associated with a decrease in MEK1/2 phosphorylation and an increase in c-Raf phosphorylation at S259 (an inhibitory site). Based on the current findings integrated with previous findings in the IMCD, we now report a 33-node vasopressin signaling network involved in vasopressin regulation of IMCD function.
WATER TRANSPORT across the renal collecting duct is controlled by the peptide hormone vasopressin, largely through the long-and short-term regulation of the apical water channel aquaporin-2 (AQP2) (24) . Long-term regulation refers to changes in total abundance of AQP2 over a period of days. Short-term regulation refers to changes in AQP2-mediated water transport over periods of minutes through regulation of trafficking of AQP2 vesicles to and from the apical plasma membrane. Beyond vasopressin's role in transport regulation, the growing recognition that vasopressin regulates proliferation of normal inner medullary collecting duct (IMCD) cells (2) as well as of renal cysts derived from collecting duct cells (36) or cysts formed from renal epithelial cells grown in culture (21) brings renewed interest to vasopressin signaling mechanisms in collecting duct cells.
A preliminary vasopressin signaling network in the renal IMCD, based on proteomic analysis and the existing literature, has been published in our previous paper (29) (see DISCUSSION for full details). The effects of vasopressin are a consequence of binding of vasopressin to basolateral V2 receptors. Although other processes have been proposed (22) , many of the vasopressin effects are believed to be consequent to activation of the heterotrimeric G protein G␣s (GNAS) and to increases in intracellular Ca 2ϩ via calmodulin (8) . Oligonucleotide microarrays in IMCDs isolated from rat kidneys revealed a significant level of expression of kinases in the Akt and MAP kinase pathways (37) . These kinases and several elements that regulate them are well-studied in many tissues, and their roles in neoplastic diseases have spurred the production of high-quality antibodies for their study. Here, we used these antibodies for immunochemical measurements coupled with fluorometric measurements of intracellular Ca 2ϩ in freshly isolated IMCD cells to expand our understanding of the vasopressin signaling network.
METHODS

Animals and IMCD Preparation
Animal procedures were approved by National Heart, Lung, and Blood Institute Animal Care and Use Committee (no. H-0110). Male Sprague-Dawley rats (200 -300 g) were injected intraperitoneally with furosemide (5 mg/rat) 20 min before decapitation and removal of kidneys. Furosemide dissipates the hypertonic medullary osmolality toward plasma osmolality level (ϳ290 mosmol/kgH 2O), thereby preventing osmotic shock to the cells upon isolation of IMCDs (31) . IMCDs were isolated from renal medullas as described (6) after digestion (3 mg/ml collagenase B, 2,000 U/ml hyaluronidase, 250 mM sucrose, 10 mM triethanolamine, pH 7.6) at 37°C with continuous stirring for 75-90 min. IMCDs were sedimented by low-speed centrifugation (70 g for 20 s), separating them from the lighter non-IMCD cells. IMCD pellets were washed and sedimented twice in sucrose buffer (250 mM sucrose, 10 mM triethanolamine, pH 7.6), followed by buffer exchange into 290 mosmol/ kgH 2O bicarbonate buffer (7).
Stimuli and Inhibitors
All experiments were performed in a pH-and temperature-controlled chamber with gentle mixing under an atmosphere of 95% air-5% CO 2 at 37°C. IMCD samples were incubated in 290 mosmol/ kgH 2O bicarbonate buffer in the absence or presence of 0.1 M EGF, 1 nM dDAVP, 0.1 mM 8-(4-chlorophenylthio)-cAMP (cpt-cAMP) for 1, 2, 5, 10, 15, or 30 min. For inhibitor studies, IMCD samples were incubated in 290 mosmol/kgH 2O bicarbonate buffer in the absence or presence of 25 M LY294002, 10 M H-89, 50 M BAPTA-AM, or 25 M W-7 for 25 min before addition of 1 nM dDAVP or 0.1 mM cpt-cAMP for 5 min.
Antibodies
The antibodies used are summarized in Supplementary Table 1 (the online version of this article contains supplemental data).
Immunoblotting
Immunoblotting was performed as described (11) . Briefly, after solubilization in Laemmli buffer, IMCD protein samples (15-20 g ) were resolved by SDS-PAGE gel electrophoresis on 10 or 4 -15% polyacrylamide gels (BioRad) and transferred electrophoretically onto nitrocellulose membranes. The membranes were then blocked with Odyssey blocking buffer (Li-Cor, Lincoln, NE), rinsed, and probed with primary antibody overnight at room temperature. After a washing, blots were incubated with species-specific fluorescently labeled secondary antibodies Alexa Fluor 680 (Molecular Probes, Eugene, OR) used at 1:5,000 for detection of all primary antibodies. Fluorescence was imaged and quantified using a Li-Cor Odyssey Imaging System.
Densitometry and Statistical Analysis
A net intensity value of each immunoblot band was quantified using Odyssey application software. Log 2 ratio or log2 normalized ratio of experimental band intensity over control band intensity was calculated for each data point. The log 2 normalized ratio was performed such that the phosphoprotein values were prenormalized to the total protein values: log 2 [(Fep/Fcp)/(Fet/Fct)] where F ϭ band intensity, e ϭ experiment, c ϭ control, p ϭ phosphoprotein, and t ϭ total protein. In time course experiments, we tested for significant differences at each time point by paired t-test. Each experimental value had its own contemporaneous control. For nontime course experiments, paired t-test or one-way ANOVA with Bonferroni contrasts was performed on log 2 ratio or log2 normalized ratio as appropriate. P value Ͻ0.05 was considered significant. The number of replicates (n) reported in the figures indicates the number of separate IMCD suspension preparations studied.
Immunofluorescence Confocal Microscopy
Immunofluorescence confocal microscopy was performed as described (42) . IMCD samples and kidney slices were fixed with 4% paraformaldehyde overnight and processed using paraffin as the embedding agent. Confocal fluorescence images were taken using a Zeiss LSM 510 microscope (Carl Zeiss MicroImaging, Thornwood, NY).
Imaging of Intracellular Ca 2ϩ in Isolated IMCD Segments
Microdissected IMCDs were transferred to Cell-Tak-coated petri dishes and incubated with 10 M Fluo-4/AM (Molecular Probes) in HEPES-buffered isolation fluid (in mM: 118 NaCl, 5 HEPES, 5 KCl, 2.5 Na 2HPO4, 2 CaCl2, 1.2 MgSO4, 5.5 glucose, 5 Na acetate, pH 7.4 with 0.1% BSA) at room temperature for 60 min. The tubules were washed with the same solution at 37°C for another 30 min to allow deesterification. Fluo-4 fluorescence was monitored dynamically 
RESULTS
Positive Controls: Vasopressin and Epidermal Growth Factor Responses
To determine the viability of our IMCD suspension preparation, we tested the ability of vasopressin to alter AQP2 phosphorylation and the ability of epidermal growth factor (EGF) to activate the MAP and Akt kinases. (35) . We confirmed the presence of the ERK1/2 MAP kinase pathway components in IMCDs by immunofluorescence staining on tissue sections (Supplementary Fig. 1 ). In our IMCD suspensions, EGF elicited a biphasic increase in ERK1/2 phosphorylation at T202 and Y204, indicative of activation ( Fig. 2A) . EGF also induced a biphasic increase in S217/221 phosphorylation of MEK1/2, the kinase responsible for ERK1/2 activation (Fig. 2B ). In addition, there were a biphasic increase in activating phosphorylation of c-Raf (the upstream kinase of MEK1/2) at S338 and a small decrease in inhibitory phosphorylation of c-Raf at S259 (Fig. 2C) . The feedback mechanisms responsible for the biphasic behavior are unknown. EGF did not measurably affect either p38 MAPK or JNK phosphorylation ( Supplementary Fig. 2 ). The presence of Akt and its upstream activator, phosphoinositide 3-kinase (PI3K) p110␥, in IMCDs was confirmed by immunofluorescence staining on tissue sections ( Supplementary Fig. 3 ). In IMCD suspensions, EGF also increased Akt phosphorylation at T308 and S473, both activating sites (Fig. 3) . Thus, EGF strongly activated both the ERK1/2 MAP kinase pathway and Akt in IMCD cell suspensions. We conclude that rat native IMCDs in suspension respond appropriately to both vasopressin and EGF.
Vasopressin Increases Akt Activation
The vasopressin analog dDAVP increased Akt activation in IMCD suspensions as evidenced by a biphasic increase in Akt phosphorylation at T308 and S473 (Fig. 4) . Maximal activation was seen 5-10 min after dDAVP addition. Akt activation is generally dependent on localized production of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) through PI3K. When IMCD suspensions were pretreated with an inhibitor of PI3K, LY294002, Akt phosphorylation at both sites was markedly diminished and the dDAVP-induced increase was eliminated (Fig. 5 ). In addition, experiments were performed to assess the phosphorylation of Akt's downstream substrates, detected by a phospho-(S/T) Akt substrate (RXRXXpS/pT motif) antibody (Fig. 5) . A marked inhibition of Akt substrate phosphorylation by LY294002 was observed. There appeared to be a small increase in Akt substrate phosphorylation in response to dDAVP. However, when we immunoblotted for known Akt substrates (GSK-3␣/␤, Bad, TSC2, MDM2, and FoxO1), no change in their phosphorylation was detected in response to dDAVP addition ( Supplementary Fig. 4 ).
cAMP Increases Akt Activation
The cAMP analog cpt-cAMP mimicked dDAVP with regard to phosphorylation at S473, but did not significantly increase phosphorylation at T308 (Fig. 6 ).
H-89 Increases Akt Activation
We tested whether the PKA inhibitor H-89 inhibits dDAVP-mediated activation of Akt. As shown in Fig. 7 , H-89 did not inhibit the effect, but instead strongly increased Akt phosphorylation at T308. This suggests that PKA is not responsible for increased Akt phosphorylation in the presence of vasopressin or that H-89 has nonspecific effects that obscure its effect on PKA.
Vasopressin Causes Spike-Like Increases in Intracellular Ca 2ϩ ; BAPTA and W-7 Block Akt Activation
Dynamic measurements in microdissected rat IMCDs using the calcium-sensitive fluorophore Fluo-4 revealed aperiodic spikelike increases in intracellular Ca 2ϩ that were accelerated by vasopressin, confirming findings of Yip (41) [Fig. 8A and Supplementary Video (http://dir.nhlbi.nih.gov/papers/lkem/ ca_spikes_video/)]. Pretreatment with the intracellular Ca 2ϩ chelator BAPTA or the calmodulin inhibitor W-7 inhibited dDAVPinduced increases in Akt phosphorylation at both sites (Fig. 8, B and C). 
Elevated Osmolality Increases Akt Activation
An increase in incubation medium osmolality from 290 to 490 mosmol/kgH 2 O (addition of NaCl) increased Akt activation, with an increase in Akt phosphorylation at T308 and S473 (Fig. 9 ). T308 phosphorylation increased more than S473 phosphorylation, in contrast to the dDAVP and cAMP effects on Akt activation (S473 Ն T308).
Vasopressin Decreases ERK1/2 and MEK1/2 Activation
The vasopressin analog dDAVP reduced ERK1/2 phosphorylation at T202 and Y204 (Fig. 10A) . This response was associated with a fall in MEK1/2 phosphorylation at S217/ 221 (Fig. 10B) . Preincubation with the PI3K inhibitor LY294002 did not inhibit dDAVP-mediated inactivation of ERK1/2 and MEK1/2 phosphorylation, and in fact independently decreased ERK1/2 and MEK1/2 phosphorylation ( Supplementary Fig. 5 ).
cAMP Decreases ERK1/2 and MEK1/2 Activation
Addition of cpt-cAMP reproduced the effects seen with dDAVP ( Fig. 11) , suggesting that the inhibition of the MAP kinase pathway by vasopressin is mediated by cAMP.
Vasopressin Does Not Affect p38 MAPK or JNK Phosphorylation
dDAVP did not alter p38 MAPK and JNK phosphorylation (Fig. 12) . p38 MAPK phosphorylation has been reported to be increased by high osmolality (17, 28) . To provide a positive control for p38 MAPK activation, we switched IMCD suspensions from a solution with osmolality 290 to 490 mosmol/ Fig. 9 . Elevated osmolality increases Akt activation. An increase in incubation medium osmolality from 290 to 490 mosmol/kgH2O (by addition of NaCl) significantly increased Akt phosphorylation at T308 and S473 (2 and 5 min). *Statistically significant. Fig. 10 . Vasopressin decreases ERK1/2 and MEK1/2 activation; 1 nM dDAVP significantly decreased ERK1/2 phosphorylation at T202 and Y204 (1 and 15 min; A) and MEK1/2 phosphorylation at S217/221 (1 min; B) . *Statistically significant. kgH 2 O. High osmolality increased p38 MAPK phosphorylation at T180 and Y182 with no effect on ERK1/2 or JNK phosphorylation (Fig. 13 ).
Vasopressin and cAMP Increase c-Raf Phosphorylation at Serine-259
The kinase c-Raf is a mediator of MEK1/2 phosphorylation in many cell types and is strongly expressed in the renal IMCD (37) . c-Raf has multiple activating and inhibitory sites (4) . Figure 14A shows the effects of dDAVP on phosphorylation of S338 (an activating site) and S259 (an inhibitory site). dDAVP did not affect the level of phosphorylation at S338, but increased phosphorylation at S259. cpt-cAMP produced similar responses (Fig. 14B) . The dDAVP-and cpt-cAMP-induced phosphorylation at S259 was blocked by the PKA inhibitor H89 (Fig. 15, A and B) . However, dDAVP-induced phosphorylation at S259 was not blocked by the PI3K inhibitor LY294002 (Fig. 15C) . These findings point to a role for PKA but not Akt in c-Raf inactivation.
DISCUSSION
Here, we demonstrated that the V2 receptor-selective vasopressin analog dDAVP affects states of activation of both the Akt and ERK1/2 MAP kinase pathways in native rat renal IMCD cells. Akt activation is increased, whereas ERK1/2 activation is decreased under the conditions of this study. Existing knowledge connects vasopressin (top) with AQP2 (bottom) via the V2 receptor (AVPR2). The heterotrimeric G protein ␣ subunit GNAS and the corresponding G␤/G␥ complex dissociate and become activated. GNAS in its GTP-bound form activates at least two adenylyl cyclases in IMCD, ADCY3 (14) and ADCY6 (3). The former is activated by Ca 2ϩ calmodulin while the latter is inhibited by Ca 2ϩ . These enzymes mediate production of cAMP, increasing cAMP concentration either locally or globally within the cell. cAMP is degraded by cyclic nucleotide phosphodiesterases PDE1 and PDE4 in IMCD cells (37) . cAMP binds to the regulatory subunit of PKA (PRKAR). Several PKA regulatory subunits are expressed in the IMCD, although PRKAR1A is the most abundant (37) . cAMP binding to the regulatory subunit removes its inhibition of the catalytic subunit (presumably PRKACA), thereby activating kinase activity. Although there are presumably many PKA targets, a well-documented one is AQP2 at serine-256 (13) . cAMP can also bind to and activate RapGEF3 (Epac1), which is strongly expressed in the IMCD in contrast to very low expression of RapGEF4 (Epac2) (37) . Another important vasopressindependent signaling process is intracellular Ca 2ϩ mobilization, which is also downstream from the V2 receptor AVPR2. This process is mediated by releasing of Ca 2ϩ from the endoplasmic reticulum via the ryanodine-sensitive Ca 2ϩ release channel RYR1 (8) . The increase in intracellular Ca 2ϩ is manifest as a series of aperiodic Ca 2ϩ spikes (41) [confirmed in this paper (Fig. 8A) ]. The rise in intracellular Ca 2ϩ increases activation of calmodulin (CALM1, CALM2, and CALM3 have the same amino acid sequence) and activates various calmodulinregulated proteins including myosin light chain kinase (MYLK), ADCY3, and phosphodiesterase-1 (PDE1). MYLK phosphorylates the B isoform of the regulatory light chain of nonmuscle myosin (MRLCB) (5) . MRLC isoforms regulate conventional nonmuscle myosin II including myosin II-A (MYH9) and myosin II-B (MYH10), both expressed in the IMCD (5). Myosin II isoforms are actin-dependent motors that are involved in organization of the actin cytoskeleton and are believed to be involved with AQP2 trafficking. In this paper, we add further information implicating both the PI3K/Akt pathway and the ERK1/2 MAP kinase pathway in vasopressin signaling in the IMCD. The PI3K/Akt pathway is activated by vasopressin (green nodes), while the ERK1/2 MAP kinase pathway is inhibited by vasopressin (red nodes). Changes in both pathways were relatively small as assessed by whole cell immunoblotting, but were extraordinarily consistent in the many experiments carried out in this study. Small but consistent changes are compatible with important physiological functions, considering the likelihood that these pathways can be activated in very localized subregions of the cell where changes may be much larger than seen in whole cell measurements.
Several prior studies investigated the role of vasopressin in regulation of the ERK1/2 MAP kinase pathway. Depending on the cell preparation and conditions, vasopressin has been found either to increase (38) , to decrease (39), or to have no effect (20) on ERK1/2 activation in cultured kidney cells. In the present paper, we show in freshly isolated IMCDs that vasopressin normally inhibits ERK1/2 activation. One factor that could play a role in vasopressin-mediated inhibition of ERK1/2 and MEK1/2 phosphorylation is PKA-mediated inhibition of c-Raf (10) (Fig. 16) . We demonstrated in this study that dDAVP enhances the phosphorylation of c-Raf at S259, an inhibitory event. This event was reproduced by cAMP (Fig.  11) , suggesting that the inhibition of c-Raf is downstream from vasopressin-induced cAMP production. H-89 (a PKA inhibitor) decreased vasopressin-and cAMP-triggered phosphorylation of c-Raf at S259 (Fig. 15, A and B) . Inhibition of c-Raf activity by phosphorylation at S259 can also be mediated by Akt (43) . In the present study, Akt was activated by vasopres- Fig. 13 . Effects of high osmolality on MAP kinase activation. An increase in incubation medium osmolality from 290 to 490 mosmol/ kgH2O (by addition of NaCl) significantly increased p38 MAPK phosphorylation at T180 and Y182 (2 to 15 min; A) with no effect on ERK1/2 phosphorylation (B), JNK1 phosphorylation (C), or JNK2/3 phosphorylation (D). *Statistically significant. sin in a PI3K-dependent manner. However, vasopressin-induced phosphorylation of c-Raf at S259 was not blocked by the PI3K inhibitor LY294002 (Fig. 15C ). In addition, PI3K inhibition did not increase ERK1/2 and MEK1/2 activation or block the decreases mediated by vasopressin ( Supplementary  Fig. 5 ). Another possible mechanism by which cAMP might contribute to regulation of ERK1/2 and MEK1/2 is a downstream effect of cAMP-mediated Epac1 activation of Rap1 (Fig. 16 ). Rap1 inhibits c-Raf by competing with Ras (27) . However, Rap1 can also activate B-Raf (26) , resulting in MEK1/2 activation. The effects of Epac1 and Rap1 activation on the MAP kinase pathway in IMCD cells require further study.
Vasopressin increased Akt phosphorylation at two sites (T308 and S473), both associated with activation of kinase activity. The network shown in Fig. 16 summarizes hypothetical mechanisms that could be responsible for Akt activation based on studies in other cell types and the present study (indicated by dashed edges). Conceivably, the coupling could be mediated through several different downstream effects of vasopressin: 1) Ca 2ϩ oscillations in the cell (33); 2) calmodulin activation (9); 3) release of activated ␣ and ␤/␥ subunit complexes in association with G protein activation by the V2 receptor (1, 18, 32); 4) local or global increases in cAMP (12, 19) ; or 5) activation of the GPCR interactor ␤-arrestin (30) . Chelation of intracellular Ca 2ϩ with BAPTA or inhibition of calmodulin with W-7 markedly diminished Akt phosphorylation at both of the key activating sites (Fig. 8, B and C) . This finding is consistent with previous studies that established a role for Ca 2ϩ in regulation of Akt via effects on PI3K activation (33) . Ca 2ϩ /calmodulin-regulated Akt activation has also been reported to be mediated through mechanisms other than those involving calmodulin-activated kinases or PI3K (9) . In contrast, Akt phosphorylation was not inhibited by the PKA inhibitor H-89 in the present study (Fig. 7) , suggesting that the activation of Akt is not mediated by PKA. In agreement with earlier studies on hyperosmolality-induced Akt activation in rat inner medulla (34) , an elevation in medium osmolality from 290 to 490 mosmol/kgH 2 O increased Akt phosphorylation at T308 and S473 (Fig. 9) . Interestingly, T308 phosphorylation increased more than S473 phosphorylation, in contrast to the dDAVP and cAMP effects on Akt activation (S473 Ն T308). This observation leads to speculation that vasopressin activates Akt through a different signaling pathway from hyperosmolality. The downstream substrates of vasopressin-induced Akt activation were investigated by immunoblotting for known Akt substrates (GSK-3␣/␤, Bad, TSC2, MDM2, and FoxO1). However, no change was found after dDAVP addition ( Supplementary  Fig. 4 ). Further studies are required to identify the downstream targets of PI3K/Akt pathway activation in response to vasopressin in IMCDs. Interestingly, it has been recently shown that phosphorylation of Akt (at both T308 and S473) and its substrate GSK-3␤ (at S9) were increased in IMCD suspensions of rats with lithium-induced nephrogenic diabetes insipidus (23) . This change in Akt and GSK-3␤ phosphorylation, however, might not be directly related to vasopressin effects due to the fact that lithium treatment leads to various other changes in the kidney, including change in local osmolality in the renal medulla.
The present study was not designed to address signaling mechanisms in autosomal dominant polycystic kidney disease (ADPKD). However, the findings regarding the role of intracellular Ca 2ϩ in vasopressin signaling may be relevant to the pathogenesis of cyst formation and growth and are therefore discussed here. It has been hypothesized that a proximate event in the disordered signaling responsible for cyst growth in ADPKD is a reduction in the intracellular Ca 2ϩ level due to loss of polycystin-mediated Ca 2ϩ entry (40) . This reduction in Ca 2ϩ is proposed to decrease Akt activation, as was seen in the present study when intracellular free Ca 2ϩ concentration was reduced by BAPTA-mediated chelation. This model of ADPKD signaling assumes that intracellular Ca 2ϩ is relatively invariant in a minute-by-minute time scale. However, in the present study we confirmed the observation of Yip (41) to rise to the Ca 2ϩ release threshold and would decrease the spike frequency, a prediction that has not yet been tested. Ca 2ϩ oscillations in the cells raise technical issues that are difficult to address experimentally. Ca 2ϩ -dependent enzymes such as myosin light chain kinase are rapidly activated and deactivated in response to the spikes. Thus, it is difficult to assess the net effect of this very dynamic pattern of Ca 2ϩ release using steady-state measurements on mixtures of cells that are experiencing changes in intracellular Ca 2ϩ at different times. In the same way, it is possible that vasopressin-induced 
